Loading
Life sciences · Journal article
Frontiers in Immunology · October 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background Mesenchymal stem cells (MSCs) have emerged as promising therapeutic agents for infectious diseases owing to their antimicrobial, immunomodulatory, and tissue regenerative properties. Beyond their well-established role in tissue repair, MSCs and their secretome directly influence pathogen clearance through the secretion of antimicrobial peptides, extracellular vesicles, iron-sequestration mechanisms, and modulation of both innate and adaptive immune responses. Knowledge gap Despite extensive preclinical investigations, MSC responses are highly pathogen-dependent, with outcomes that can be beneficial, neutral, or even detrimental depending on the infectious context. The heterogeneity in MSC efficacy across different pathogens underscores the need for a nuanced understanding of their mechanisms of action and the development of strategies to optimize therapeutic outcomes. Key findings In bacterial infections, MSCs generally promote pathogen clearance and attenuate inflammation. Conversely, antiviral effects are often indirect, primarily involving the regulation of cytokine-driven immunopathology rather than direct inhibition of viral replication. Fungal and parasitic infections exhibit more complex interactions, with some pathogens exploiting MSCs as protective niches or reprogramming their immunological functions. Emerging strategies, including priming, genetic engineering, and cell-free secretome approaches, show promise in enhancing MSC efficacy. However, heterogeneity in cell source, manufacturing processes, potency, dosing, and timing remains a significant translational barrier. Conclusion Future development of MSC-based therapies should shift from a universal, one-size-fits-all approach toward pathogen-specific, tailored cellular or cell-free products. This transition requires the establishment of standardized potency assays, optimized dosing protocols, and clinically meaningful endpoints. Adopting a pathogen-oriented framework will be essential for advancing MSCs as effective anti-infective agents, especially in the face of rising antimicrobial resistance.